Table 2.
Selected CAR T cell clinical trials for GB.
| Target | Identifier | Tumor | Country | N | Results |
|---|---|---|---|---|---|
| NKG2D | NCT04270461 | GB | USA | 10 | Not yet recruiting |
| CD147 | NCT04045847 | GB | China | 31 | Not recruiting |
| B7H3 | NCT04077866 | GB | China | 40 | Not yet recruiting |
| EGFRVIII | NCT02844062 | GB | China | 20 | Unknown, not disclosed |
| NCT02664363 | GB | United States | 3 | Terminated, not disclosed | |
| NCT03726515 | GB | United States | 7 | Active, not recruiting | |
| NCT01454596 | GB | United States | 18 | Completed, results (closed) | |
| EpHA2 | NCT02575261 | GB | China | 60 | Completed, not disclosed |
| GD2 | NCT03252171 | GB | China | 60 | Completed, not disclosed |
| HER2 | NCT01109095 | GB | United States | 16 | Completed, not disclosed |
| NCT03389230 | GB | United States | 42 | Recruiting, not disclosed | |
| IL13Rα2 | NCT04003649 | GB | United States | 60 | Recruiting, not disclosed |
| NCT02208362 | GB | United States | 92 | Recruiting, not disclosed |
B7H3; CD147; Epidermal growth factor receptor variant III (EGFRvIII); EPH receptor A2 (EpHA2); Disialoganglioside 2 (GD2); HER2; Interleukin 13 receptor α2 (IL13Rα2), Natural-killer group 2, member D receptor protein (NKG2D).